Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma

Tyrosine kinase inhibitors (TKIs) that target pro-angiogenic molecules, such as vascular endothelial growth factor receptors (VEGFRs), in the tumour microenvironment induce apoptosis by inhibiting tumour cell proliferation and angiogenesis [1]. TKIs are effective in treating a range of tumour types, including advanced hepatocellular carcinoma (HCC) [2 –5]. HCC accounts for the majority of cases of primary liver cancer, which is the sixth most common cancer and the fourth most common cause of cancer-related death worldwide [6].

Source: Cancer Treatment Reviews - May 14, 2019 Category: Cancer & Oncology Authors: Lorenza Rimassa, Romano Danesi, Tiziana Pressiani, Philippe Merle Tags: Anti-Tumour Treatment Source Type: research